HOUSTON , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced detailed results of its first-in-human Phase 1 clinical trial of AVB-S6-500 in healthy volunteers. As previously announced, the trial met the safety and tolerability
- Merger completed; now operating as Aravive, Inc. (Nasdaq:ARAV), a clinical-stage biopharmaceutical company advancing innovative oncology therapeutics - FDA Fast Track designation granted for lead candidate, AVB-S6-500 - Initiation of the Phase 1b portion of a Phase
The combined company, Aravive, Inc. , to trade on Nasdaq under ticker symbol “ARAV” beginning October 16, 2018 , concurrent with a 1-for-6 reverse split of common shares HOUSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Aravive Biologics, Inc. and Versartis, Inc.
HOUSTON, TEXAS (August 20, 2018): Aravive Biologics, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track Designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer. “Gaining Fast Track Designation is an important
Aravive Biologics, Inc. announced today that the company has completed both the single ascending dose and repeat dose portions of its Phase 1 study of AVB-S6-500 in healthy volunteers. The study met the safety and tolerability endpoints for the trial.
Versartis enters into merger agreement with Aravive Biologics to form a clinical-stage biopharmaceutical company advancing innovative oncology therapeutics. View presentation >
Versartis, Inc. (NASDAQ:VSAR), and Aravive Biologics, Inc., today jointly announced that they have entered into a definitive agreement under which Aravive will merge with a wholly owned subsidiary of Versartis in an all-stock transaction. The transaction will result in a clinical stage,
Aravive Biologics, Inc. announced today that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase I study (32 subjects). The objective of this study is to evaluate the safety,
Aravive Biologics, Inc., a clinical-stage biotechnology company focused on development of treatments for cancer and fibrotic diseases, today announced two new appointments to the company’s scientific advisory board. Kimberly L. Blackwell, M.D., Vice President, Early Phase Oncology and
Aravive Biologics, Inc., a clinical-stage biotechnology company focused on development of treatments for cancer and fibrotic diseases, today announced the initiation of a Phase 1 clinical trial of AVB-S6-500 (previously referred to as Aravive-S6). The study is being conducted in the United States
